To improve the lives of patients and their families.

To provide medicines that slow, stop, or revert the progression.

By targeting the pathology of toxic misfolded proteins.

Our Programs

Structured for Success

Based in the biotech hub of San Diego, our in-house expertise of our people and global collaborations with academic and industry partners allow us to discover novel therapeutic targets and develop innovative therapeutics.  

About the Company


Neuropore Announces Successful Completion of Phase l with its Lead Compound NPT200-11 March 7, 2016

NPT200-11 was well tolerated in 55 volunteers after oral administration.

See All News


Presentation by Neuropore CEO, Dr. Dieter Meier March 17th-20th, 2016

Dr. Dieter Meier presented at the 10th Congress on Controversies in Neurology (CONy), in Lisbon, Portugal.

See All Events

Neuropore Publications

Translational imaging biomarkers in rodent models of Parkinson's September 2-5, 2015

123I‐ioflupane SPECT/CT imaging of the dopamine transporter and 18F‐FDG PET/CT imaging of metabolism. World Molecular Imaging Congress, Honolulu Hawaii.

See All Publications

Our Major Partnerships

Ever Neuro Pharma
The Michael J. Fox Foundation for Parkinson's Research
Neuropore Video

Our Technology

Learn about Neuropore’s two part development strategy targeting misfolded proteins -- the key pathological culprit(s) underlying neurodegenerative disorders.

Learn More See All Videos